原发性胆汁性胆管炎中肝生化指标升高与不良临床结局的纵向关系:一项基于人群的研究
该研究基于Komodo医疗数据库纳入3974例原发性胆汁性胆管炎成人患者,评估纵向监测肝生化指标和纤维化评分是否提供额外预后价值。中位随访2.5年,结果显示ALP、ALT、AST、TB、APRI和FIB-4超过既定阈值的时间比例增加与不良结局风险升高相关,且ALT、AST、TB、APRI和FIB-4升高在所有ALP分层中均与不良结局风险增加相关。
要点
- ALP、ALT、AST、TB、APRI和FIB-4超出阈值的时间比例增加与不良结局风险升高相关。
- ALT、AST、TB、APRI和FIB-4升高在所有ALP分层中均与不良结局风险增加相关。
- 结论强调除指南推荐的初始治疗反应外,持续监测多个肝生化指标和纤维化评分对指导及时治疗决策的重要性。
核心结论
- 多个肝生化指标和纤维化评分持续升高与不良临床结局风险增加相关,强调在指南推荐的初始治疗反应之外持续监测的重要性,以指导及时治疗决策并改善PBC管理。
研究设计与样本
- 基于Komodo医疗数据库识别成人PBC患者,纳入3974例,其中女性88.2%,平均年龄59.4岁,中位随访2.5年。
- 采用Cox比例风险模型分析随访期间肝生化指标和纤维化评分超过阈值的时间比例与首次发生肝失代偿住院、肝移植或死亡复合终点的关系。
- 在ALP分层(ALP≤正常上限[ULN];ALP>ULN至≤1.67×ULN;ALP>1.67×ULN)内,分别用多变量Cox风险模型评估时变协变量与复合终点的关联。
主要发现
- ALP、ALT、AST、TB、APRI和FIB-4超过既定阈值的幅度和持续时间增加与不良结局风险升高相关。
- ALT、AST、TB、APRI和FIB-4升高在所有ALP分层中均与不良结局风险增加相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated liver biochemistries are associated with increased risk of negative outcomes in patients with primary biliary cholangitis (PBC). AIMS: To evaluate whether longitudinal monitoring of liver biochemistries and fibrosis scores provides additional prognostic value and to assess the relationship between the degree of elevation of multiple biomarkers within different alkaline phosphatase (ALP) strata. METHODS: Adults with PBC were identified from Komodo's Healthcare Map. A Cox proportional hazards model examined time to first occurrence of hospitalisation due to hepatic decompensation, liver transplantation, or death as a function of the proportion of time during follow-up that liver biochemistries and fibrosis scores exceeded thresholds. Within ALP strata (ALP ≤ upper limit of normal [ULN]; ALP>ULN to ≤ 1.67 × ULN; ALP > 1.67 × ULN), separate multivariate Cox hazard models assessed the association between time-varying covariates and the composite endpoint. RESULTS: Overall, 3974 patients were included; 88.2% were female, with a mean age of 59.4 years. The median follow-up was 2.5 years. Increasing magnitude and duration beyond established thresholds of ALP, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), AST/platelet ratio index (APRI) and fibrosis-4 (FIB-4) were associated with increased risk of negative outcomes. Elevated ALT, AST, TB, APRI and FIB-4 were associated with increased risk of negative outcomes across all ALP strata. CONCLUSIONS: Prolonged elevation of multiple hepatic biomarkers and fibrosis scores is associated with a greater risk of negative clinical outcomes, underscoring the importance of ongoing monitoring beyond the guideline-recommended initial treatment response to guide timely treatment decisions and improve PBC management.
引用
- Kowdley KV, Victor DW, MacEwan JP, et al. Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population-Based Study. Aliment Pharmacol Ther. 2025. PMID: 40176393. doi:10.1111/apt.70120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。